Methylprednisolone disposition kinetics in patients with acute spinal cord injury

Pharmacotherapy

Volumn 18, Issue 1, 1998, Pages 16-22

  Segal, Jack L ^a   Maltby, Brian F ^a   Langdorf, Mark I ^a   Jacobson, Ray ^a   Brunnemann, Sherry R ^a   Jusko, William J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; ISOPRENALINE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADOLESCENT; ADULT; ARTICLE; CHEMICAL REACTION KINETICS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROLOGICAL COMPLICATION; SPINAL CORD INJURY; STEROID THERAPY;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHYLPREDNISOLONE; MIDDLE AGED; SPINAL CORD INJURIES;

EID: 0031964223     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Young W, Bracken MB. The second national acute spinal cord injury study. J Neurotrauma 1992;9(suppl 1):S397-405.
2. Anonymous. Drugs for acute spinal cord injury. Med Lett Drugs Ther 1993;35(902):72-3.
3. Bracken MB, Shepard MJ, Collins WF, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second national acute spinal cord injury study. J Neurosurg 1992;76:23-31.
4. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury randomized controlled trial. National acute spinal cord injury study. JAMA 1997;277(20):1597-1604.
5. Gerhart KA, Johnson RL, Menconi J, et al. Utilization and effectiveness of methylprednisolone in a population-based sample of spinal cord injured persons. Paraplegia 1995; 33(6):316-21.
6. Iwai A, Monafo WW, Eliasson SG. Methylprednisolone treatment of experimental spinal cord injury. Paraplegia 1993;31:417-29.
7. Levy ML, Gans W, Wijesinghe HS, et al. Use of methylprednisolone as an adjunct in the management of patients with penetrating spinal cord injury: outcome analysis. Neurosurgery 1996;39(6):1141-8.
8. Galandiuk S, Raque G, Appel S, et al. The two-edged sword of large dose steroids for spinal cord trauma. Ann Surg 1993;218(4):419-27.
9. Young W, Kume-Kick J. Glucocorticoid therapy of spinal cord injury. Ann NY Acad Sci 1994;743:241-65.
10. Gumbleton M, Sneader W. Pharmacokinetic considerations in rational drug design. Clin Pharmacokinet 1994;26(3):161-8.
11. Rosebaum SE, Carter AA, Dudley MN. Population pharmacokinetics. Drug Dev Industrial Pharm 1995;21(9):1115-41.
12. George ER, Scholten DJ, Buechler CM, et al. Failure of methylprednisolone to improve the outcome of spinal cord injuries. Am Surgeon 1995;61:659-64.
13. Shapiro SA. Methylprednisolone for spinal cord injury [letter]. J Neurosurg 1992;77:324-7.
14. Lyons MK, Partington MD, Meyer FB. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury [letter]. N Engl J Med 1990;323(17):1207-9.
15. Sapolsky RM, Pulsinelli WA. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. Science 1985;229:1397-1400.
16. Ratain MJ. Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol 1992;19(4 suppl 11):8-13.
17. Segal JL. Clinical pharmacology of spinal cord injury. In: Young RR, Woolsey RM, eds. Diagnosis and management of disorders of the spinal cord, 1st ed. Philadelphia: WB Saunders, 1995:414-38.
18. Mathias CJ, Christensen NJ, Frankel HL, et al. Cardiovascular control in recently injured tetraplegics in spinal shock. Q J Med 1979;48(190):273-87.
19. Woolsey RM, Young RR. The clinical diagnosis of disorders of the spinal cord. In: Young RR, Woolsey RM, eds. Diagnosis and management of disorders of the spinal cord, 1st ed. Philadelphia: WB Saunders, 1995:135-44.
20. Ferry JJ, Della-Coletta AA, Weber DJ, et al. Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. J Clin Pharm 1994;34:1109-15.
21. El-Yazigi A, Bouchama A, Al-Abdely H, et al. Impaired elimination of atenolol in a nephropathic patient with selfmedication overdose. J Clin Pharm 1993;33(5):450-2.
22. Edgren B, Tilelli J, Gehrz R. Intravenous lidocaine overdosage in a child. J Toxicol Clin Toxicol 1986;24(1):51-8.
23. Ebling WJ, Szefler SJ, Jusko WJ. Analysis of cortisol, methylprednisolone and methylprednisolone hemisuccinate: absence of effects of troleandomycin on ester hydrolysis. J Chromatogr 1984;305:271-80.
24. Purves RD. Optimum numerical integration methods of estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharm Biopharm 1992;20:211-26.
25. Humphrey MJ, Smith DA. Role of metabolism and pharmacokinetic studies in the discovery of new drugs - present and future perspectives. Xenobiotica 1992;22:743-55.
26. Segal JL, Brunnemann SR. Clinical pharmacokinetics in patients with spinal cord injury. Clin Pharmacokinet 1989;17(2):109-29.
27. Chen TC, Mackic JB, McComb JG, Giannotta SL, Weiss MH, Zlokovic BV. Cellular uptake and transport of methylprednisolone at the blood-brain barrier. Neurosurgery 1996;38(2):348-54.
28. Ludwig EA, Kong A, Camara DS, et al. Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. J Clin Pharm 1993,33:805-10.
29. Defer F, Barré J, Ledudal P, et al. Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. Eur Neurol 1995;35:143-8.
30. Hall ED, Wolf DL, Braughler JM. Effects of a single large dose of methylprednisolone sodium succinate on experimental post-traumatic spinal cord ischemia. Dose-response and time-action analysis. J Neurosurg 1984;61:124-30.
31. Braughler JM, Lainer MJ. The effects of large doses of methylprednisolone on neurologic recovery and survival in the Mongolian gerbil following three hours of unilateral carotid occlusion. Cent Nerv Syst Trauma 1986;3:153-61.
32. Segal JL, Brunnemann SR. Altered catecholamine levels are associated with changes in hepatic oxidative metabolism in humans with spinal cord injury. J Clin Pharm 1991;31:841-71.
33. Bloom KK, Freed MM. Liver enzyme abnormalities in spinal cord injury. J Am Paraplegia Soc 1989;12(1):11-14.
34. Segal JL. Spinal cord injury: are interleukins a molecular link between neuronal damage and ensuing pathobiology? Perspect Biol Med 1993;36(2):222-40.
35. Segal JL, Milne N, Brunnemann SR. Gastric emptying is impaired in patients with spinal cord injury. Am J Gastroenterol 1995;90(3):466-70.
36. Segal JL, Brunnemann SR, Gray DR, et al. Impaired absorption of intramuscularly administered gentamicin in spinal cord injury. Curr Ther Res 1986;39(6):961-9.
37. Segal JL, Brunnemann SR. 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury. Pharmacotherapy 1997;17(3):415-23.